Target Price | $158.10 |
Price | $144.30 |
Potential | 9.56% |
Number of Estimates | 34 |
34 Analysts have issued a price target Arm 2026 . The average Arm target price is $158.10. This is 9.56% higher than the current stock price. The highest price target is $220.50 52.81% , the lowest is $77.31 46.43% . | |
A rating was issued by 41 analysts: 24 Analysts recommend Arm to buy, 14 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Arm stock has an average upside potential 2026 of 9.56% . Most analysts recommend the Arm stock at Purchase. |
39 Analysts have issued a sales forecast Arm 2026 . The average Arm sales estimate is $4.8b . This is 17.13% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $6.1b 46.98% , the lowest is $4.4b 5.58% .
This results in the following potential growth metrics:
2025 | $4.0b | 23.94% |
---|---|---|
2026 | $4.8b | 20.46% |
2027 | $5.9b | 21.44% |
2028 | $6.9b | 17.60% |
2029 | $9.1b | 31.38% |
2030 | $11.7b | 29.57% |
2031 | $15.4b | 31.42% |
2032 | $14.6b | 5.06% |
27 Analysts have issued an Arm EBITDA forecast 2026. The average Arm EBITDA estimate is $2.3b . This is 140.19% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $2.9b 202.91% , the lowest is $1.8b 87.95% .
This results in the following potential growth metrics and future EBITDA Margins:
2025 | $916m | 364.97% |
---|---|---|
2026 | $2.3b | 152.51% |
2027 | $3.0b | 30.09% |
2028 | $4.0b | 32.70% |
2029 | $5.1b | 26.47% |
2030 | $6.0b | 19.45% |
2031 | $7.6b | 25.76% |
2025 | 22.86% | 275.16% |
---|---|---|
2026 | 47.92% | 109.62% |
2027 | 51.33% | 7.12% |
2028 | 57.92% | 12.84% |
2029 | 55.76% | 3.73% |
2030 | 51.40% | 7.82% |
2031 | 49.19% | 4.30% |
36 Analysts have issued a Arm forecast for earnings per share. The average Arm EPS is $1.72 . This is 160.61% higher than earnings per share in the financial year 2025. The highest EPS forecast is $2.23 237.88% , the lowest is $1.40 112.12% .
This results in the following potential growth metrics and future valuations:
2025 | $0.75 | 158.62% |
---|---|---|
2026 | $1.72 | 129.33% |
2027 | $2.30 | 33.72% |
2028 | $2.87 | 24.78% |
2029 | $3.69 | 28.57% |
2030 | $4.59 | 24.39% |
2031 | $5.64 | 22.88% |
2032 | $5.40 | 4.26% |
Current | 218.64 | 38.61% |
---|---|---|
2026 | 83.97 | 61.59% |
2027 | 62.87 | 25.13% |
2028 | 50.30 | 19.99% |
2029 | 39.07 | 22.33% |
2030 | 31.47 | 19.45% |
2031 | 25.60 | 18.65% |
2032 | 26.70 | 4.30% |
Based on analysts' sales estimates for 2026, the Arm stock is valued at an EV/Sales of 30.33 and an P/S ratio of 30.93 .
This results in the following potential growth metrics and future valuations:
Current | 35.53 | 13.17% |
---|---|---|
2026 | 30.33 | 14.62% |
2027 | 24.98 | 17.66% |
2028 | 21.24 | 14.97% |
2029 | 16.17 | 23.88% |
2030 | 12.48 | 22.82% |
2031 | 9.49 | 23.91% |
2032 | 10.00 | 5.33% |
Current | 36.23 | 12.96% |
---|---|---|
2026 | 30.93 | 14.63% |
2027 | 25.47 | 17.66% |
2028 | 21.66 | 14.97% |
2029 | 16.49 | 23.88% |
2030 | 12.72 | 22.82% |
2031 | 9.68 | 23.91% |
2032 | 10.20 | 5.33% |
Analyst | Rating | Action | Date |
---|---|---|---|
Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Sep 11 2025 |
Seaport Global |
➜
Buy
|
Initiated | Aug 11 2025 |
Needham |
Hold
➜
Hold
|
Unchanged | Jul 31 2025 |
Rosenblatt |
Buy
➜
Buy
|
Unchanged | Jul 31 2025 |
Raymond James |
Outperform
➜
Outperform
|
Unchanged | Jul 31 2025 |
Keybanc |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Sep 11 2025 |
Initiated
Seaport Global:
➜
Buy
|
Aug 11 2025 |
Unchanged
Needham:
Hold
➜
Hold
|
Jul 31 2025 |
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Jul 31 2025 |
Unchanged
Raymond James:
Outperform
➜
Outperform
|
Jul 31 2025 |
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Jul 31 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jul 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.